Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
#TTOO 🔥 offering news! Buy the dip? $ttoo
John Sperzel, CEO of this shit company- contact informaiton
Email Address: jsperzel@t2biosystems.com
Phone Number 781-457-1220
Totally agree.. but maybe before jail he can get one or two more reverse splits done
What's with the volume!!! Over 20,000,000 dollar traded on TTOO today.
Ttoo
Why would anyone buy into this Ttoo BULLSHIT.? They just scammed a lot of people out of their money. WAKE UP PEOPLE!
10 cents coming! Then another R/S...
It'll Happen without a doubt $TTOO coming soon to a theater near you! 💥🏁🎬️
a boulder over TTOO's head, at any moment they could declare the delisting from Nasdaq to OTC. Is it worth the risk of holding a title like that? I say no !!!
Ttoo
T2 Biosystems shares plummeted 47% on forecasts of lower revenue in the third-quarter.
The stock is down 93% on the year so far. Trading was paused for volatility twice Friday before resuming at 9:55 a.m. ET.
they are almost all companies born in OTC. when you move from Nasdaq to OTC, it is always seen and judged as a downgrading of the company. so not good.
however TTOO will not go on OTC...
Plenty of big companies trade on the OTC my dude.
I hope you're joking...
if you go OTC you're done for. you're done with the big investors, and also retail. they would take you to a cap. market value of one or two million dollars. you would no longer have the problem of the dollar price, the shorts will definitively destroy you...
especially if you switch from Nasdaq to OTC. it would be an irreparable defeat...
Not necessarily...OTC can give them time to rebuild and re list on Nasdaq if they choose. But I don't think this Co is long for this earth.
The hearing usually takes 35-40 days...
they have to sell the company by the end of the year...
or it will be OTC, and therefore the end of the company...
Extension until hearing. At hearing they need to demonstrate how they will get compliant. How do you see them finding 22 million in market cap?
$TTOO--Keeping my short going here...Target $2
having paid 20k, they will have an extension...
There is no remedy. Can't create 22 million in market cap out of thin air.
nothing is decided...
there's this:
The Company has paid the applicable fee of $20,000 and expects to promptly file a request for a new hearing before the Panel, which request will suspend any further action by Nasdaq at least pending the issuance of the Panel's decision and the expiration of any extension that could be granted by the Panel to the Company following the hearing.
The Company's common stock will remain listed and eligible for trading on Nasdaq pending the outcome of the hearing. There is no guarantee, however, that the Panel will grant the Company's request to continue to list or that the Company will demonstrate compliance with all applicable listing criteria prior to the expiration of any extension that may be granted by the Panel for this purpose...
Game over
OTC bound.
Ttoo
PERFORMANCE
5 Day
-6.64%
1 Month
-29.77%
3 Month
-88.80%
YTD
-97.23%
1 Year
-97.71%
Still a POS!!!!
Where are the catalysts to drive thisnhigher?
How high can we go today? Any guess?
at the beginning of the year it was trading at $140, a rebound is very likely. naturally only with any news would it launch a missile into orbit...
I'm hoping for a big reverse soon,like it happened with LIFW.
Ttoo
Down
D
O
W
N
Under$4......coming!
So obvious that some posters try @nything to recoup.
A close of $4.6+ will be great for tomorrow's run.
The earth is flat
Ttoo
You say it will never go below 5$. Well it is at $4.20. You have any other helpful BS INFO?
Just watching for right now corvatsch
Patience will pay off huge profits.
Followers
|
163
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5812
|
Created
|
12/17/14
|
Type
|
Free
|
Moderators |
This section maintained by INV4 Saving lives and improving healthcare by empowering clinicians to effectively treat patients faster At T2 Biosystems, our mission is to save lives and improve healthcare by empowering clinicians to get patients on the right therapy faster. We come to work every day to solve critical needs in healthcare diagnostics with innovative solutions built on our game-changing T2 Magnetic Resonance (T2MR®) detection technology. Sepsis claims more lives annually than breast cancer, prostate cancer, and AIDS combined. We’re focused on eradicating deaths due to sepsis by developing tools that help identify the most common and deadly sepsis-causing pathogens faster than ever before. Speed is critical in sepsis management. The faster patients receive effective treatment, the more likely they are to survive and have better outcomes. Better yet, early targeted therapy for bloodstream infections may prevent the progression to sepsis altogether. Our blood tests provide actionable results in just 3 to 5 hours. The only other way to identify the species-specific diagnosis requires a blood culture, which can take 1 to 5 days or more. Today, T2 Biosystems panels are getting patients on the right therapy faster, and the expedited identification of negative test results allows rapid de-escalation of unneeded therapy. In partnership with hospitals around the world, T2 Biosystems technology is uniquely positioned to strike a huge blow to sepsis and the hundreds of thousands of lives it takes each year. Our T2Bacteria® and T2Candida® Panels run on the automated T2Dx® Instrument. They are the first and only FDA-cleared blood tests that identify sepsis-causing pathogens without the wait for blood culture. As hospitals continue to adopt our technology, it will represent a paradigm shift that can potentially result in thousands of patients going home to their families instead of the tragic, and potentially avoidable, alternative. We have an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens About our name: T2 refers to the measurement of the reaction of water molecules in the presence of magnetic fields. This is what our T2MR technology measures, and it is the inspiration behind our company’s name. T2Dx Instrument Breakthrough technology enabling direct detection from whole blood The FDA-cleared T2Dx® Instrument is a fully automated, walk away, clinical multiplex benchtop diagnostic system capable of running tests directly from whole blood. The benefits of the T2Dx Instrument include
The T2Dx Instrument serves nearly 200 hospitals worldwide and is powered by T2 Magnetic Resonance (T2MR®) technology. ================================== Innovative T2MR®applications currently in development T2 Biosystems has multiple diagnostic applications in development, all designed to enable further breakthroughs in rapid and accurate therapy for patients. The diagnostics are focused on critical, unmet needs in healthcare, where solutions can serve a dual role of improving patient care while reducing costs. T2Resistance® Panel: T2 Biosystems has partnered with Allergan and CARB-X to develop panels with additional bacterial species and resistance markers. The T2Resistance Panel detects gram-negative and gram-positive resistance markers and is currently available for research use only (RUO) in the U.S. and CE marked on November 20, 2019. T2Cauris™ Panel RUO: Direct detection of the emerging superbug Candida auris in patient skin and blood samples and hospital environmental samples are now available for research use only (RUO) assays. The CDC* validated the T2Cauris Panel RUO swab test on patient skin samples and published their 2017 findings in Mycoses. 1. ANSON FUNDS MANAGEMENT LP Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise investment discretion, over the assets of others, in excess of $100 Million. Major institutions include financial holdings companies, banks, insurance companies, mutual fund managers, portfolio managers, self managed pension and endowment funds. The report is limited to equity securities, including common and equivalents, convertible preferred and convertible bonds. The report does not include fixed income, real estate, or cash equivalents. Reports are filed within 45 days after calendar quarter end with the vast majority of updates occurring near the 45th day of the quarter. About Institutional Holdings Institutional Holdings information can be used to gauge the volatility and value on the company’s stock. https://www.nasdaq.com/market-activity/stocks/ttoo/institutional-holdings Contact 101 Hartwell Avenue |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |